Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Inclusion Criteria: * Histologically or cytologically confirmed prostate cancer * Documented progression on at least one prior hormone treatment, AND at least one taxane based chemotherapy regimen, or patient's refusal of chemotherapy treatment * Male, Age \> 18 years * ECOG (Eastern Cooperative Oncology Group) performance score of 0-2 * Adequate bone marrow, renal and hepatic function * Men of childbearing potential must consent to use barrier contraception while on treatment and for 90 days thereafter Exclusion Criteria: * Prior treatment with NRX 194204 or bexarotene (Targretin) * Presence of parenchymal brain metastases * History of prior malignancy within the past 5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or superficial bladder or other stage I or stage II cancer in complete remission for at least 12 months * Patients with a history of unstable or newly diagnosed angina pectoris, documented history of current serious arrhythmia or congestive heart failure or myocardial infarction within 6 months of enrollment * Known HIV or hepatitis B or C infection * Life expectancy \< 3 months * Patients with any history of thyroid disease, pituitary disease or treatment with thyroid replacement hormone * Patients with a history of pancreatitis or at significant risk of developing pancreatitis